| 2026 |
| 11/13 | 3,117 | 3,188 | 3,101 | 3,172 | +1.08% | 2,834,700 | - | +6.12% |
| 11/12 | 3,069 | 3,142 | 3,069 | 3,138 | +2.68% | 2,235,300 | - | +5.59% |
| 11/11 | (IR情報)15:30 (訂正・数値データ訂正)「2027年3月期第1四半期決算短信〔IFRS〕(連結)」の一部訂正について |
| 11/11 | (IR情報)15:30 (訂正・数値データ訂正)「2027年3月期第2四半期(中間期)決算短信〔IFRS〕(連結)」の一部訂正について |
| 11/11 | 3,062 | 3,103 | 3,039 | 3,056 | +0.53% | 2,427,700 | - | +3.35% |
| 11/10 | (IR情報)15:30 IntraBio Inc.の買収に係るブリッジローンの借入について |
| 11/10 | 3,066 | 3,075 | 3,022 | 3,040 | -0.52% | 1,962,900 | - | +3.33% |
| 11/09 | 3,041 | 3,117 | 3,041 | 3,056 | +2.48% | 3,156,600 | - | +4.26% |
| 11/06 | 3,159 | 3,188 | 2,961 | 2,982 | -6.58% | 3,775,400 | - | +2.02% |
| 11/05 | (5%ルール)アペリオ・グループ・エルエルシー(Aperio Group,…(0.15%)ブラックロック(ネザーランド)BV(BlackRock (Neth…(0.29%)ブラックロック(ルクセンブルグ)エス・エー(Black…(0.08%)ブラックロック・アセット・マネジメント・アイルラ…(1.17%)ブラックロック・アセット・マネジメント・カナダ・…(0.18%)ブラックロック・インスティテューショナル・トラス…(1.27%)ブラックロック・インベストメント・マネジメント(…(0.11%)ブラックロック・インベストメント・マネジメント(…(0.53%)ブラックロック・ジャパン(2.04%)ブラックロック・ファンド・アドバイザーズ(Black…(2.39%)ブラックロック・ファンド・マネジャーズ・リミテッ…(0.2%) |
| 11/05 | 3,147 | 3,219 | 3,130 | 3,192 | +5.42% | 3,852,800 | - | +9.35% |
| 11/04 | 3,030 | 3,051 | 3,000 | 3,028 | +0.1% | 3,305,100 | - | +4.23% |
| 11/02 | 3,082 | 3,106 | 2,990 | 3,025 | +0.43% | 3,767,600 | - | +4.31% |
| 10/30 | (IR情報)10:00 (訂正・数値データ訂正)「2027年3月期業績予想および年間配当予想の修正(増配)に関するお知らせ」の一部訂正について |
| 10/30 | 2,939 | 3,042 | 2,937 | 3,012 | +0.77% | 3,768,200 | - | +3.97% |
| 10/29 | (IR情報)16:15 剰余金の配当(中間配当)に関するお知らせ |
| 10/29 | (IR情報)13:00 2027年3月期業績予想および年間配当予想の修正(増配)に関するお知らせ |
| 10/29 | (IR情報)13:00 2026年度第2四半期(中間期)決算説明資料 |
| 10/29 | (IR情報)13:00 22027年3月期第2四半期(中間期)決算補足資料 |
| 10/29 | (IR情報)13:00 2027年3月期第2四半期(中間期)決算短信〔IFRS〕(連結) |
| 10/29 | 2,985 | 3,054 | 2,959 | 2,989 | -0.07% | 7,158,400 | - | +3.32% |
| 10/28 | 3,030 | 3,053 | 2,991 | 2,991 | -1.51% | 2,146,800 | - | +3.42% |
| 10/27 | 3,016 | 3,054 | 3,000 | 3,037 | -0.46% | 2,430,200 | - | +5.05% |
| 10/26 | 3,036 | 3,079 | 3,014 | 3,051 | +0.49% | 1,649,900 | - | +5.72% |
| 10/23 | 3,097 | 3,097 | 3,026 | 3,036 | +0.26% | 2,751,900 | - | +5.42% |
| 10/22 | 3,017 | 3,049 | 3,001 | 3,028 | +0.23% | 2,438,300 | - | +5.43% |
| 10/21 | 3,020 | 3,050 | 2,996 | 3,021 | +1.41% | 3,443,800 | - | +5.48% |
| 10/20 | 2,939 | 2,979 | 2,927 | 2,979 | +1.36% | 1,777,500 | - | +4.27% |
| 10/19 | 2,963 | 2,975 | 2,919 | 2,939 | +0.17% | 2,071,200 | - | +3.05% |
| 10/16 | 2,895 | 2,948 | 2,886 | 2,934 | +1.35% | 2,844,400 | - | +2.95% |
| 10/15 | 2,817 | 2,896 | 2,800 | 2,895 | +3.76% | 6,215,800 | - | +1.58% |
| 10/14 | 2,791 | 2,800 | 2,762 | 2,790 | -0.89% | 2,263,900 | - | -2.14% |
| 10/13 | 2,783 | 2,818 | 2,756 | 2,815 | +2.55% | 2,908,200 | - | -1.54% |
| 10/09 | 2,758 | 2,778 | 2,734 | 2,745 | -0.87% | 3,305,800 | - | -4.22% |
| 10/08 | 2,800 | 2,804 | 2,728 | 2,769 | +0.22% | 3,365,500 | - | -3.65% |
| 10/07 | 2,724 | 2,779 | 2,711 | 2,763 | 0% | 3,910,100 | - | -4.03% |
| 10/06 | 2,694 | 2,763 | 2,687 | 2,763 | +3.83% | 4,590,400 | - | -4.23% |
| 10/05 | (IR情報)15:00 米国IntraBio社の完全子会社化に関するお知らせ |
| 10/05 | 2,768 | 2,784 | 2,649 | 2,661 | -4.49% | 6,383,300 | - | -7.96% |
| 10/02 | 2,813 | 2,832 | 2,766 | 2,786 | -2.31% | 3,322,400 | - | -4% |
| 10/01 | 2,850 | 2,878 | 2,805 | 2,852 | -0.66% | 2,743,400 | - | -1.89% |
| 09/30 | 2,827 | 2,883 | 2,808 | 2,871 | +1.13% | 3,565,700 | - | -1.34% |
| 09/29 | 2,877 | 2,885 | 2,822 | 2,839 | -2.71% | 2,838,900 | - | -2.51% |
| 09/28 | 2,924 | 2,956 | 2,915 | 2,918 | -0.68% | 3,096,000 | - | +0.1% |
| 09/25 | 2,940 | 2,963 | 2,929 | 2,938 | +0.69% | 2,423,900 | - | +0.86% |
| 09/24 | 2,945 | 2,958 | 2,915 | 2,918 | -1.25% | 3,084,900 | - | +0.31% |
| 09/18 | 2,971 | 2,985 | 2,947 | 2,955 | -0.94% | 3,861,900 | - | +1.76% |
| 09/17 | 2,917 | 2,988 | 2,902 | 2,983 | +3.15% | 2,058,600 | - | +2.9% |
| 09/16 | (IR情報)15:00 「ブイタマークリーム」の国内における小児(12歳未満)アトピー性皮膚炎に対する用法・用量追加の製造販売承認取得について |
| 09/16 | (IR情報)15:00 組み換えタンパクワクチン「コブゴーズ筋注」の国内における一部変更承認の取得について |
| 09/16 | 2,888 | 2,918 | 2,871 | 2,892 | -0.41% | 2,366,600 | - | -0.03% |
| 09/15 | 2,914 | 2,948 | 2,900 | 2,904 | +1.75% | 2,690,100 | - | +0.48% |
| 09/14 | 2,840 | 2,862 | 2,818 | 2,854 | +0.96% | 1,950,100 | - | -1.14% |
| 09/11 | 2,819 | 2,834 | 2,791 | 2,827 | -0.14% | 3,364,400 | - | -2.04% |
| 09/10 | 2,832 | 2,847 | 2,808 | 2,831 | -0.56% | 2,442,700 | - | -1.91% |
| 09/09 | 2,885 | 2,892 | 2,846 | 2,847 | -1.76% | 2,897,500 | - | -1.25% |
| 09/08 | 2,923 | 2,926 | 2,888 | 2,898 | -1.53% | 2,177,900 | - | +0.63% |
| 09/07 | 2,942 | 3,005 | 2,928 | 2,943 | +1.17% | 3,526,800 | - | +2.19% |
| 09/04 | 2,946 | 2,968 | 2,904 | 2,909 | -2.77% | 3,499,800 | - | +1.08% |
| 09/03 | 2,980 | 3,026 | 2,968 | 2,992 | +0.34% | 2,843,600 | - | +3.74% |
| 09/02 | 2,963 | 3,005 | 2,939 | 2,982 | +1.08% | 3,320,400 | - | +3.29% |
| 09/01 | 2,909 | 2,963 | 2,907 | 2,950 | +1.34% | 2,264,800 | - | +2.29% |
| 08/31 | 2,880 | 2,918 | 2,871 | 2,911 | -0.07% | 3,008,500 | - | +1.04% |
| 08/28 | 2,891 | 2,927 | 2,891 | 2,913 | +0.1% | 1,463,300 | - | +1.18% |
| 08/28 | (IR情報)9:00 米国政府によるグラム陰性菌感染症治療薬セフィデロコルの調達について |
| 08/27 | 2,906 | 2,934 | 2,886 | 2,910 | -0.48% | 1,519,200 | - | +1.15% |
| 08/26 | 2,932 | 2,965 | 2,908 | 2,924 | +0.45% | 1,772,900 | - | +1.7% |
| 08/25 | 2,940 | 2,960 | 2,911 | 2,911 | -0.38% | 1,506,900 | - | +1.29% |
| 08/24 | 2,920 | 2,961 | 2,912 | 2,922 | +0.1% | 1,550,400 | - | +1.71% |
| 08/21 | 2,932 | 2,951 | 2,912 | 2,919 | -0.48% | 2,335,100 | - | +1.71% |
| 08/20 | 2,905 | 2,945 | 2,897 | 2,933 | +2.59% | 2,628,000 | - | +2.3% |
| 08/19 | 2,881 | 2,881 | 2,819 | 2,859 | +0.99% | 2,447,000 | - | -0.14% |
| 08/18 | 2,800 | 2,842 | 2,789 | 2,831 | +1% | 2,106,300 | - | -1.08% |
| 08/17 | 2,851 | 2,851 | 2,791 | 2,803 | -1.02% | 1,669,800 | - | -2.06% |
| 08/14 | 2,848 | 2,851 | 2,810 | 2,832 | +0.46% | 2,184,400 | - | -1.08% |
| 08/13 | 2,837 | 2,848 | 2,793 | 2,819 | -0.07% | 3,351,900 | - | -1.61% |
| 08/12 | 2,797 | 2,834 | 2,786 | 2,821 | -0.74% | 3,478,600 | - | -1.64% |
| 08/10 | 2,822 | 2,863 | 2,803 | 2,842 | +1.14% | 2,967,300 | - | -1.04% |
| 08/07 | 2,818 | 2,858 | 2,794 | 2,810 | -0.57% | 3,710,900 | - | -2.19% |
| 08/06 | 2,750 | 2,833 | 2,732 | 2,826 | +2.47% | 3,006,000 | - | -1.6% |
| 08/05 | 2,773 | 2,814 | 2,739 | 2,758 | -0.61% | 3,148,200 | - | -3.87% |
| 08/04 | 2,853 | 2,900 | 2,772 | 2,775 | -4.28% | 4,060,600 | - | -3.31% |
| 08/03 | (IR情報)15:30 2026年度第1四半期決算およびHIV事業に関するアップデート説明資料 |
| 08/03 | (IR情報)15:30 2027年3月期第1四半期決算補足資料 |
| 08/03 | (IR情報)15:30 2027年3月期第1四半期決算短信〔IFRS〕(連結) |
| 08/03 | 2,917 | 2,920 | 2,825 | 2,899 | -0.34% | 2,659,500 | - | +0.98% |
| 07/31 | 2,921 | 2,951 | 2,893 | 2,909 | -4.34% | 3,058,800 | - | +1.54% |
| 07/30 | 3,050 | 3,082 | 2,999 | 3,041 | -0.94% | 3,118,900 | - | +6.4% |
| 07/29 | 2,948 | 3,070 | 2,920 | 3,070 | +5.75% | 3,912,900 | - | +7.76% |
| 07/28 | 2,909 | 2,930 | 2,880 | 2,903 | +0.28% | 2,128,300 | - | +2.25% |
| 07/27 | 2,855 | 2,904 | 2,854 | 2,895 | +1.37% | 1,957,400 | - | +2.12% |
| 07/24 | 2,846 | 2,876 | 2,826 | 2,856 | +0.28% | 1,900,200 | - | +0.88% |
| 07/23 | (IR情報)15:30 譲渡制限付株式報酬としての自己株式の処分の払込完了について |
| 07/23 | 2,877 | 2,885 | 2,824 | 2,848 | -0.97% | 1,989,600 | - | +0.64% |
| 07/22 | 2,876 | 2,887 | 2,842 | 2,876 | -0.83% | 2,151,500 | - | +1.66% |
| 07/21 | 2,919 | 2,926 | 2,870 | 2,900 | +0.83% | 3,007,500 | - | +2.62% |
| 07/17 | 2,858 | 2,929 | 2,849 | 2,876 | +1.16% | 3,508,400 | - | +1.91% |
| 07/16 | 2,848 | 2,872 | 2,831 | 2,843 | +0.07% | 2,218,900 | - | +0.89% |
| 07/15 | 2,915 | 2,915 | 2,810 | 2,841 | -0.28% | 2,431,300 | - | +0.92% |
| 07/14 | 2,832 | 2,874 | 2,820 | 2,849 | +1.1% | 2,084,600 | - | +1.28% |
| 07/13 | 2,837 | 2,837 | 2,806 | 2,818 | -0.53% | 2,070,600 | - | +0.28% |
| 07/10 | 2,865 | 2,865 | 2,803 | 2,833 | -0.07% | 2,194,800 | - | +0.78% |
| 07/09 | 2,872 | 2,893 | 2,814 | 2,835 | -1.36% | 2,418,600 | - | +0.82% |
| 07/08 | 2,955 | 2,959 | 2,861 | 2,874 | -1.2% | 3,303,000 | - | +2.2% |
| 07/07 | 2,926 | 2,958 | 2,899 | 2,909 | -0.48% | 2,914,200 | - | +3.52% |
| 07/06 | 2,892 | 2,930 | 2,871 | 2,923 | +1.88% | 1,916,700 | - | +4.17% |
| 07/03 | 2,889 | 2,941 | 2,851 | 2,869 | +3.09% | 2,854,600 | - | +2.32% |
| 07/02 | 2,776 | 2,805 | 2,731 | 2,783 | +1.87% | 2,776,300 | - | -0.93% |
| 07/01 | 2,689 | 2,789 | 2,688 | 2,732 | -2.04% | 2,703,500 | - | -3.05% |
| 06/30 | 2,813 | 2,817 | 2,764 | 2,789 | -0.61% | 3,453,700 | - | -1.45% |
| 06/29 | 2,770 | 2,835 | 2,767 | 2,806 | +1.85% | 2,918,500 | - | -1.13% |
| 06/26 | 2,740 | 2,767 | 2,716 | 2,755 | +1.32% | 2,409,300 | - | -3.23% |
| 06/25 | 2,800 | 2,808 | 2,719 | 2,719 | -3.62% | 2,915,300 | - | -4.76% |
| 06/24 | (IR情報)17:00 譲渡制限付株式報酬としての自己株式の処分について |
| 06/24 | (IR情報)16:00 資本コストや株価を意識した経営の実現に向けた対応に関するお知らせ |
| 06/24 | 2,810 | 2,837 | 2,785 | 2,821 | +0.04% | 2,475,200 | - | -1.57% |
| 06/23 | 2,838 | 2,850 | 2,800 | 2,820 | +0.28% | 2,447,600 | - | -1.88% |
| 06/22 | 2,780 | 2,812 | 2,771 | 2,812 | +1.15% | 1,742,600 | - | -2.43% |
| 06/19 | (IR情報)14:00 抗新型コロナウイルス(SARS-CoV-2)薬ゾコーバの国内における小児用法・用量の追加承認について |
| 06/19 | 2,783 | 2,822 | 2,760 | 2,780 | -1.87% | 3,411,000 | - | -3.87% |
| 06/18 | (IR情報)13:00 新規抗真菌薬オロロフィムのグローバル第3相臨床試験(OASIS試験)における良好な結果について(速報) |
| 06/18 | 2,855 | 2,866 | 2,820 | 2,833 | 0% | 2,117,600 | - | -2.44% |